Engineered Placental MAIT Cells for CAR Therapy Survival

Solution Overview

Problem

Existing CAR-T cell therapies using peripheral blood and cord blood MAIT cells have limitations in effector activity and survivability, which can impact their therapeutic efficacy in treating various diseases and conditions.

Innovation Solution

The development of placental MAIT cells engineered to express a chimeric antigen receptor (CAR) with enhanced effector activity and survivability, allowing them to recognize specific antigens and target various molecules, including tumor antigens, microbial antigens, and molecules associated with autoimmune diseases, fibrotic diseases, and senescence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If peripheral blood and cord blood MAIT cells are used for CAR-T cell therapy, then the therapy can be implemented, but the effector activity and survivability are limited

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoideffector activity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the source parameter of MAIT cells from peripheral blood or cord blood to placental tissue. This parameter change results in MAIT cells with enhanced effector activity, improved survivability, and better therapeutic efficacy. The placental origin provides cells with superior functional characteristics compared to conventional sources.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If peripheral blood and cord blood MAIT cells are used for CAR-T cell therapy, then the therapy can be implemented, but the survivability is limited

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidsurvivability

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent changes the source parameter of MAIT cells from peripheral blood or cord blood to placental tissue. This parameter change results in MAIT cells with enhanced effector activity, improved survivability, and better therapeutic efficacy. The placental origin provides cells with superior functional characteristics compared to conventional sources.

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If conventional MAIT cells are used, then the treatment can proceed, but the lytic capabilities are insufficient

Engineering Contradiction:

Improvetreatment feasibilityVSAvoidlytic capabilities

Core Design Contradiction:

Ease of manufactureVSStrength

Solution Approach 1:

The patent changes the source parameter of MAIT cells from conventional sources to placental tissue. This parameter change results in MAIT cells with enhanced effector activity, improved survivability, and better therapeutic efficacy. The placental origin provides cells with superior functional characteristics compared to conventional sources.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250290039A1Genetically engineered placental mucosalassociated invariant t (MAIT) cells and uses thereof

Publication Date: 2025.09.18 PLURI BIOTECH LTD

AI summary

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.